Cargando…

Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study

In this study, we explored the predictive value of serum microRNA (miRNA) expression for early tumor progression during FOLFIRINOX chemotherapy and its association with overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC). A total of 132 PDAC patients of all disease stages...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Sijde, Fleur, Homs, Marjolein Y. V., van Bekkum, Marlies L., van den Bosch, Thierry P. P., Bosscha, Koop, Besselink, Marc G., Bonsing, Bert A., de Groot, Jan Willem B., Karsten, Thomas M., Groot Koerkamp, Bas, Haberkorn, Brigitte C. M., Luelmo, Saskia A. C., Mekenkamp, Leonie J. M., Mustafa, Dana A. M., Wilmink, Johanna W., van Eijck, Casper H. J., Vietsch, Eveline E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535910/
https://www.ncbi.nlm.nih.gov/pubmed/34681562
http://dx.doi.org/10.3390/ijms222010902
_version_ 1784587897723158528
author van der Sijde, Fleur
Homs, Marjolein Y. V.
van Bekkum, Marlies L.
van den Bosch, Thierry P. P.
Bosscha, Koop
Besselink, Marc G.
Bonsing, Bert A.
de Groot, Jan Willem B.
Karsten, Thomas M.
Groot Koerkamp, Bas
Haberkorn, Brigitte C. M.
Luelmo, Saskia A. C.
Mekenkamp, Leonie J. M.
Mustafa, Dana A. M.
Wilmink, Johanna W.
van Eijck, Casper H. J.
Vietsch, Eveline E.
author_facet van der Sijde, Fleur
Homs, Marjolein Y. V.
van Bekkum, Marlies L.
van den Bosch, Thierry P. P.
Bosscha, Koop
Besselink, Marc G.
Bonsing, Bert A.
de Groot, Jan Willem B.
Karsten, Thomas M.
Groot Koerkamp, Bas
Haberkorn, Brigitte C. M.
Luelmo, Saskia A. C.
Mekenkamp, Leonie J. M.
Mustafa, Dana A. M.
Wilmink, Johanna W.
van Eijck, Casper H. J.
Vietsch, Eveline E.
author_sort van der Sijde, Fleur
collection PubMed
description In this study, we explored the predictive value of serum microRNA (miRNA) expression for early tumor progression during FOLFIRINOX chemotherapy and its association with overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC). A total of 132 PDAC patients of all disease stages were included in this study, of whom 25% showed progressive disease during FOLFIRINOX according to the RECIST criteria. MiRNA expression was analyzed in serum collected before the start and after one cycle of chemotherapy. In the discovery cohort (n = 12), a 352-miRNA RT-qPCR panel was used. In the validation cohorts (total n = 120), miRNA expression was detected using individual RT-qPCR miRNA primers. Before the start of FOLFIRINOX, serum miR-373-3p expression was higher in patients with progressive disease compared to patients with disease control after FOLFIRINOX (Log2 fold difference (FD) 0.88, p = 0.006). MiR-194-5p expression after one cycle of FOLFIRINOX was lower in patients with progressive disease (Log2 FD −0.29, p = 0.044). Both miRNAs were predictors of early tumor progression in a multivariable model including disease stage and baseline CA19-9 level (miR-373-3p odds ratio (OR) 3.99, 95% CI 1.10–14.49; miR-194-5p OR 0.91, 95% CI 0.83–0.99). MiR-373-3p and miR-194-5p did not show an association with OS after adjustment for disease stage, baseline CA19-9, and chemotherapy response. In conclusion, high serum miR-373-3p before the start and low serum miR-194-5p after one cycle are associated with early tumor progression during FOLFIRINOX.
format Online
Article
Text
id pubmed-8535910
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85359102021-10-23 Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study van der Sijde, Fleur Homs, Marjolein Y. V. van Bekkum, Marlies L. van den Bosch, Thierry P. P. Bosscha, Koop Besselink, Marc G. Bonsing, Bert A. de Groot, Jan Willem B. Karsten, Thomas M. Groot Koerkamp, Bas Haberkorn, Brigitte C. M. Luelmo, Saskia A. C. Mekenkamp, Leonie J. M. Mustafa, Dana A. M. Wilmink, Johanna W. van Eijck, Casper H. J. Vietsch, Eveline E. Int J Mol Sci Article In this study, we explored the predictive value of serum microRNA (miRNA) expression for early tumor progression during FOLFIRINOX chemotherapy and its association with overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC). A total of 132 PDAC patients of all disease stages were included in this study, of whom 25% showed progressive disease during FOLFIRINOX according to the RECIST criteria. MiRNA expression was analyzed in serum collected before the start and after one cycle of chemotherapy. In the discovery cohort (n = 12), a 352-miRNA RT-qPCR panel was used. In the validation cohorts (total n = 120), miRNA expression was detected using individual RT-qPCR miRNA primers. Before the start of FOLFIRINOX, serum miR-373-3p expression was higher in patients with progressive disease compared to patients with disease control after FOLFIRINOX (Log2 fold difference (FD) 0.88, p = 0.006). MiR-194-5p expression after one cycle of FOLFIRINOX was lower in patients with progressive disease (Log2 FD −0.29, p = 0.044). Both miRNAs were predictors of early tumor progression in a multivariable model including disease stage and baseline CA19-9 level (miR-373-3p odds ratio (OR) 3.99, 95% CI 1.10–14.49; miR-194-5p OR 0.91, 95% CI 0.83–0.99). MiR-373-3p and miR-194-5p did not show an association with OS after adjustment for disease stage, baseline CA19-9, and chemotherapy response. In conclusion, high serum miR-373-3p before the start and low serum miR-194-5p after one cycle are associated with early tumor progression during FOLFIRINOX. MDPI 2021-10-09 /pmc/articles/PMC8535910/ /pubmed/34681562 http://dx.doi.org/10.3390/ijms222010902 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
van der Sijde, Fleur
Homs, Marjolein Y. V.
van Bekkum, Marlies L.
van den Bosch, Thierry P. P.
Bosscha, Koop
Besselink, Marc G.
Bonsing, Bert A.
de Groot, Jan Willem B.
Karsten, Thomas M.
Groot Koerkamp, Bas
Haberkorn, Brigitte C. M.
Luelmo, Saskia A. C.
Mekenkamp, Leonie J. M.
Mustafa, Dana A. M.
Wilmink, Johanna W.
van Eijck, Casper H. J.
Vietsch, Eveline E.
Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study
title Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study
title_full Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study
title_fullStr Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study
title_full_unstemmed Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study
title_short Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study
title_sort serum mir-373-3p and mir-194-5p are associated with early tumor progression during folfirinox treatment in pancreatic cancer patients: a prospective multicenter study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535910/
https://www.ncbi.nlm.nih.gov/pubmed/34681562
http://dx.doi.org/10.3390/ijms222010902
work_keys_str_mv AT vandersijdefleur serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT homsmarjoleinyv serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT vanbekkummarliesl serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT vandenboschthierrypp serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT bosschakoop serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT besselinkmarcg serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT bonsingberta serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT degrootjanwillemb serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT karstenthomasm serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT grootkoerkampbas serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT haberkornbrigittecm serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT luelmosaskiaac serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT mekenkampleoniejm serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT mustafadanaam serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT wilminkjohannaw serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT vaneijckcasperhj serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT vietschevelinee serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy
AT serummir3733pandmir1945pareassociatedwithearlytumorprogressionduringfolfirinoxtreatmentinpancreaticcancerpatientsaprospectivemulticenterstudy